Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2), and NF-κB (Nuclear factor kappa B), curbing the inflammatory response.
Prednisone, methylprednisolone, and hydrocortisone are the primary glucocorticoids used. Prednisone is almost exclusively given orally, and, while methylprednisolone and hydrocortisone can also be given orally, in severe cases they are given intravenously. These drugs target the entire gastrointestinal tract, inducing remission effectively, but have limitations for long-term use due to significant adverse effects such as skin thinning, cardiovascular events, and psychiatric disturbances.
Budesonide (Pulmacort), another glucocorticoid, is available in oral, rectal, and controlled-release formulations. Oral budesonide is used for ileocecal Crohn's disease, while rectal formulations are preferred for diseases limited to the rectum and left colon. It exhibits high first-pass hepatic metabolism, resulting in low systemic bioavailability and fewer side effects than conventional glucocorticoids. However, its efficacy in achieving clinical remission may be slightly lower than prednisolone.
Glucocorticoids, like prednisone, are potent anti-inflammatory agents that induce effective remission in Crohn's patients.
These bind and activate nuclear receptors, which translocate to the nucleus and interact with glucocorticoid response elements on DNA.
This interaction inhibits the transcription of proinflammatory cytokines such as TNF and inflammatory mediators such as NF-κB and phospholipase A2.
Common glucocorticoids used for treatment are prednisone, methylprednisolone, hydrocortisone, and budesonide.
Prednisone is usually administered orally, while severe cases may require intravenous methylprednisolone.
Hydrocortisone can be delivered via enemas or suppositories to target inflammation in the rectum and sigmoid colon, providing localized relief.
Budesonide, an analog of prednisolone, is often used in an enteric-release formulation that minimizes first-pass hepatic metabolism to treat ileocecal inflammation.
The prolonged use of glucocorticoids is discouraged due to potential adverse effects, including osteoporosis, arrhythmia, anxiety, and gastritis.
繁體中文
